Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center,

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up MGX-001 bioengineered FVIII construct exhibited higher FVIII activity at similar integration rates compared to wild type FVIII construct in preclinical studies;